5-Fluorouracil (i.v.), capecitabine and tegafur containing products: Pre-treatment testing to identify DPD-deficient patients at increased risk of severe toxicity
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Referral - Article 31
Fluorouracil and fluorouracil related substances (capecitabine, tegafur and flucytosine) containing medicinal products
|Human ATC code||